Search hospitals
>
Pennsylvania
>
Pittsburgh
Magee Women's Hospital of UPMC
Claim this profile
Pittsburgh, Pennsylvania 15213
Global Leader in Breast Cancer
Global Leader in Ovarian Cancer
Conducts research for Breast cancer
Conducts research for Fallopian Tube Cancer
Conducts research for Cancer
403 reported clinical trials
44 medical researchers
Summary
Magee Women's Hospital of UPMC is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Breast Cancer, Ovarian Cancer, Breast cancer, Fallopian Tube Cancer, Cancer and other specialties. Magee Women's Hospital of UPMC is involved with conducting 403 clinical trials across 537 conditions. There are 44 research doctors associated with this hospital, such as Adam Brufsky, MD, Melissa A. Burgess, Alexander B. Olawaiye, and Adam Olson.
Area of expertise
Breast Cancer
Magee Women's Hospital of UPMC has run 92 trials for Breast Cancer. Some of their research focus areas include:
Ovarian Cancer
Magee Women's Hospital of UPMC has run 53 trials for Ovarian Cancer. Some of their research focus areas include:
Top PIs
Adam Brufsky, MD
University of Pittsburgh Cancer Institute (UPCI)
2 years of reported clinical research
Melissa A. Burgess
University of Pittsburgh Cancer Institute (UPCI)
6 years of reported clinical research
Alexander B. Olawaiye
University of Pittsburgh Cancer Institute (UPCI)
3 years of reported clinical research
Adam Olson
UPMC-Shadyside Hospital
1 year of reported clinical research
Clinical Trials running at Magee Women's Hospital of UPMC
Breast Cancer
Ovarian Cancer
Cancer
Prostate Cancer
Breast cancer
Endometrial Cancer
Testicular cancer
Small Cell Lung Cancer
Pre-eclampsia
Oral Squamous Cell Carcinoma
Contrast-Enhanced Mammography
for Breast Abnormalities
One of the primary criticisms of mammography is that it leads to unneeded stress and anxiety from identification and biopsy of non-cancerous findings. Contrast-enhanced mammography (CEM) has the potential to significantly reduce biopsy rates for commonly seen benign breast lesions while preserving very high cancer detection. The investigators propose a prospective clinical study of patients with diagnostic mammograms rated as BIRADS 4A or 4B and scheduled for a biopsy, in which, prior to undergoing their scheduled biopsy, a CEM procedure is performed. The investigators will test the primary hypothesis that for soft tissue lesions (i.e. masses, asymmetries, architectural distortions) initially rated BI-RADS 4A/4B adding CEM will reduce, by at least 20%, the number of biopsy recommendations for actually benign cases and, at the same time, provide a negative predictive value (NPV) higher than 95%.
Recruiting
3 awards
Phase 4
3 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting
2 awards
Phase 3
19 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting
2 awards
Phase 3
40 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Magee Women's Hospital of UPMC?
Magee Women's Hospital of UPMC is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Breast Cancer, Ovarian Cancer, Breast cancer, Fallopian Tube Cancer, Cancer and other specialties. Magee Women's Hospital of UPMC is involved with conducting 403 clinical trials across 537 conditions. There are 44 research doctors associated with this hospital, such as Adam Brufsky, MD, Melissa A. Burgess, Alexander B. Olawaiye, and Adam Olson.
Where is Magee Women's Hospital of UPMC located?
**Directions to Magee-Womens Hospital of UPMC, Pittsburgh, PA:** - From the north, start on I-279 S and follow signs for I-579 S/Veterans Bridge. - Continue onto US-19 Truck S/US-22 E/US-30 E/PA-8 S, and take exit 72B for Oakland Ave. - Turn left onto Oakland Ave, then right onto Fifth Ave. The hospital will be on your left.
Who should I call to ask about financial aid or insurance network?
**Financial Assistance at Magee Women's Hospital of UPMC:** - For assistance, contact the Patient Financial Services Center at 1-800-371-8359 or email PatientFinancialServicesCenter@upmc.edu. - Services include help with governmental assistance, payment plans, reviewing the Financial Assistance program, and support for urgent services for uninsured or underinsured patients. - Assistance with health insurance applications through the Health Insurance Marketplace is available via UPMC's Certified Application Counselors. **Insurance Inquiries:** - Hospital operator: 412-641-1000 - Referral line: 866-696-2433 - UPMC Health Plan bill inquiries: Member Services at 1-888-876-2756 or TTY 711. **During Your Stay:** - For questions, please consult your case manager.
What insurance does Magee Women's Hospital of UPMC accept?
Magee Women's Hospital of UPMC accepts insurance plans from Highmark, Blue Cross Blue Shield, Aetna, Cigna, United Healthcare, and UPMC Health Plan. After June 30, 2019, most UPMC doctors and hospitals in the greater Pittsburgh and Erie areas will be out-of-network for Highmark commercial members with specific plans. Highmark or Blue Cross Blue Shield Medicare Advantage plan members will also lose full, in-network access to UPMC after this date.
What awards or recognition has Magee Women's Hospital of UPMC received?
Magee Women's Hospital of UPMC, located in Pittsburgh, Pennsylvania, is renowned for its dedication to women's health, partnering with the Magee-Womens Research Institute and Foundation. It excels in areas such as HIV prevention, ovarian cancer therapies, and women's cancers. The hospital is also celebrated for its environmental efforts, being a member of Practice Greenhealth since 2015, and for its exceptional care, evidenced by three Women's Choice Awards in obstetrics, cancer care, and inpatient experience.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.